Gilead stock falls 10% after disappointing lung cancer drug trial results

Shares of Gilead took a hit as the stock fell more than 10% on Monday following disappointing results from a late-stage trial of its key lung cancer drug, Trodelvy. The trial failed to significantly extend the lives of patients with…